Welcome, to the Cell & Gene Therapy Revolution.
C> is at an Inflection Point
Innovation at an Unprecedented pace: Advances in viral delivery systems and autologous cell therapy opened up the first generation of treatments. Now, multiplex gene editing, iPSCs-based cell therapies, and new delivery vehicles are driving the second and third waves. As the Science begins to mature, the opportunities for drug development, are limitless.
Record-breaking Funding: In 2020, there was a record-breaking $19.9B invested into C>*. That’s more than $54M/day fueling this innovation engine and accelerating the journey from concept, to commercially available therapies.
Biotech's Reputation is Back: The mRNA success story did more than just precipitate the end of the pandemic. It brought about a general awareness that Biotech is critical to our way of life. Increasingly, the talented minds of today and tomorrow are seeing a meaningful purpose in Biotech, applying themselves to this next generation of science.
It's an exciting time to be in Cell & Gene Therapy. And at PharmaCentaur C>, we are proud to help.
*Alliance for Regenerative Medicines Annual report